journal
https://read.qxmd.com/read/38796194/donor-lymphocyte-infusion-after-allogeneic-haematopoietic-cell-transplantation-for-haematological-malignancies-basic-considerations-and-best-practice-recommendations-from-the-ebmt
#21
REVIEW
Simona Pagliuca, Christoph Schmid, Nicole Santoro, Federico Simonetta, Giorgia Battipaglia, Thierry Guillaume, Raffaella Greco, Francesco Onida, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha, Jurgen Kuball, Mette D Hazenberg, Annalisa Ruggeri
Since the early description of three patients with relapsed leukaemia after allogeneic haematopoietic cell transplantation (HCT) who obtained complete remission after donor lymphocyte infusions (DLIs), the added value of this procedure to induce or maintain graft-versus-leukaemia immunity has been undisputed. For more than 30 years, DLIs have become common practice as prophylactic, pre-emptive, or therapeutic immunotherapy. However, as with many aspects of allogeneic HCT, centres have developed their own routines and practices, and many questions related to the optimal applications and toxicity, or to the immunobiology of DLI induced tumour-immunity, remain...
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796193/oral-azacitidine-compared-with-standard-therapy-in-patients-with-relapsed-or-refractory-follicular-helper-t-cell-lymphoma-oracle-an-open-label-randomised-phase-3-study
#22
RANDOMIZED CONTROLLED TRIAL
Jehan Dupuis, Emmanuel Bachy, Franck Morschhauser, Guillaume Cartron, Noriko Fukuhara, Nicolas Daguindau, René-Olivier Casasnovas, Sylvia Snauwaert, Remy Gressin, Christopher P Fox, Francesco Annibale d'Amore, Philipp B Staber, Olivier Tournilhac, Krimo Bouabdallah, Catherine Thieblemont, Marc André, Shinya Rai, Daisuke Ennishi, Argyrios Gkasiamis, Mitsufumi Nishio, Luc-Matthieu Fornecker, Marie-Helene Delfau-Larue, Nouhoum Sako, Sebastien Mule, Laurence de Leval, Philippe Gaulard, Kunihiro Tsukasaki, François Lemonnier
BACKGROUND: Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed to compare the oral form of azacitidine with investigator's choice standard therapy (ICT; ie, gemcitabine, bendamustine, or romidepsin) in patients with relapsed or refractory TFHL. METHODS: Patients older than 18 years with relapsed or refractory TFHL (angioimmunoblastic T-cell lymphoma, follicular lymphoma, or nodal T-cell lymphoma with phenotype, ie, positive with two or more markers among CD10, BCL6, CXCL13, PD1, or ICOS) based on the 2017 WHO classification of haematological neoplasms, with an Eastern Cooperative Oncology Group performance status score of 0-3, were recruited in university hospitals from five European countries and from Japan...
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796192/trends-opportunities-and-challenges-of-clinical-trials-for-haematological-diseases-in-china
#23
JOURNAL ARTICLE
Jianwei Qi, Lijun Liu, Jiajia Gao, Yi Yue, Zhen Song, Lei Zhang, Tao Cheng
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796191/step-out-of-the-shadows-a-call-for-action-for-rare-diseases
#24
EDITORIAL
Francesca Granata, Rayan Bou-Fakhredin, Maria Domenica Cappellini, Irene Motta
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796190/striking-the-right-balance
#25
EDITORIAL
Alexander Coltoff
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796189/correction-to-lancet-haematol-2018-5-e232
#26
(no author information available yet)
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796188/eltrombopag-cyclosporin-a-in-treating-severe-aplastic-anaemia-authors-reply
#27
LETTER
Phillip Scheinberg
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796187/the-effects-of-upward-revision-of-haemoglobin-thresholds-for-anaemia-in-blood-donations-authors-reply
#28
LETTER
Katherine L Fielding, Sabine Braat, Sant-Rayn Pasricha
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796186/eltrombopag-cyclosporin-a-in-treating-severe-aplastic-anaemia
#29
LETTER
Krishna Sai Sathiamoorthy, S Manikandan
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796185/the-effects-of-upward-revision-of-haemoglobin-thresholds-for-anaemia-in-blood-donations
#30
LETTER
Tomohiko Sato, Nelson Hirokazu Tsuno, Ryu Yanagisawa, Shin-Ichiro Fujiwara
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38796184/long-term-strategies-for-individuals-with-sickle-cell-disease
#31
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
June 2024: Lancet Haematology
https://read.qxmd.com/read/38677302/isatuximab-carfilzomib-lenalidomide-and-dexamethasone-in-patients-with-newly-diagnosed-transplantation-eligible-multiple-myeloma-skylark-a-single-arm-phase-2-trial
#32
MULTICENTER STUDY
Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G Richardson, Noopur Raje
BACKGROUND: Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk. METHODS: This single-arm phase 2 trial was done at three cancer centres (two hospitals and a cancer institute) in Boston (MA, USA)...
June 2024: Lancet Haematology
https://read.qxmd.com/read/38701819/sickle-cell-disease-in-india-current-status-and-progress
#33
JOURNAL ARTICLE
Dipty Jain, Mihir Gupta, Manisha Madkaikar, Rabindra K Jena, Naveen Khargekar, Santosh L Saraf, Lakshmanan Krishnamurti, Kalpna Gupta
No abstract text is available yet for this article.
May 2024: Lancet Haematology
https://read.qxmd.com/read/38701818/doggedly-first-hand-a-medical-memoir-that-does-not-step-outside-itself
#34
JOURNAL ARTICLE
Catherine Lucas
No abstract text is available yet for this article.
May 2024: Lancet Haematology
https://read.qxmd.com/read/38697732/clotting-and-bleeding-in-beh%C3%A3-et-s-syndrome
#35
JOURNAL ARTICLE
Jagdish R Nair, Zoe J Syrimi, Caroline V Cotton, Robert J Moots
No abstract text is available yet for this article.
May 2024: Lancet Haematology
https://read.qxmd.com/read/38697731/diagnosis-treatment-and-surveillance-of-diamond-blackfan-anaemia-syndrome-international-consensus-statement
#36
REVIEW
Marcin W Wlodarski, Adrianna Vlachos, Jason E Farrar, Lydie M Da Costa, Antonis Kattamis, Irma Dianzani, Cristina Belendez, Sule Unal, Hannah Tamary, Ramune Pasauliene, Dagmar Pospisilova, Josu de la Fuente, Deena Iskander, Lawrence Wolfe, Johnson M Liu, Akiko Shimamura, Katarzyna Albrecht, Birgitte Lausen, Anne Grete Bechensteen, Ulf Tedgard, Alexander Puzik, Paola Quarello, Ugo Ramenghi, Marije Bartels, Heinz Hengartner, Roula A Farah, Mahasen Al Saleh, Amir Ali Hamidieh, Wan Yang, Etsuro Ito, Hoon Kook, Galina Ovsyannikova, Leo Kager, Pierre-Emmanuel Gleizes, Jean-Hugues Dalle, Brigitte Strahm, Charlotte M Niemeyer, Jeffrey M Lipton, Thierry M Leblanc
Diamond-Blackfan anaemia (DBA), first described over 80 years ago, is a congenital disorder of erythropoiesis with a predilection for birth defects and cancer. Despite scientific advances, this chronic, debilitating, and life-limiting disorder continues to cause a substantial physical, psychological, and financial toll on patients and their families. The highly complex medical needs of affected patients require specialised expertise and multidisciplinary care. However, gaps remain in effectively bridging scientific discoveries to clinical practice and disseminating the latest knowledge and best practices to providers...
May 2024: Lancet Haematology
https://read.qxmd.com/read/38697730/alexis-thompson-advancing-care-for-sickle-cell-disease
#37
JOURNAL ARTICLE
Udani Samarasekera
No abstract text is available yet for this article.
May 2024: Lancet Haematology
https://read.qxmd.com/read/38697729/diversity-equity-and-inclusion-in-ash-guidelines-authors-reply
#38
LETTER
Jeremy W Jacobs, Garrett S Booth, Julie K Silver
No abstract text is available yet for this article.
May 2024: Lancet Haematology
https://read.qxmd.com/read/38697728/diversity-equity-and-inclusion-in-ash-guidelines
#39
LETTER
Matthew D Seftel, Deirdra Terrell, Adam Cuker, Matthew Cheung, Menaka Pai
No abstract text is available yet for this article.
May 2024: Lancet Haematology
https://read.qxmd.com/read/38697727/universal-health-coverage-for-children-with-cancer
#40
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
May 2024: Lancet Haematology
journal
journal
49595
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.